Compare Sanofi SA (SNY) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Upwork Inc — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Upwork Inc trades at $8.37 (market cap $1.04B). The key difference: Sanofi SA is far larger — about 100.3× Upwork Inc's market cap, and Sanofi SA pays a 5.55% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| SNY | UPWK | |
|---|---|---|
Market Cap | $104.30B | $1.04B |
Sector | Health | Industrials |
52-Week High | $52.34 | $22.11 |
52-Week Low | $41.33 | $7.84 |
Enterprise Value | $124.19B | $806.15M |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Upwork (UPWK) stock is trading at $8.385, down 14.7% on the day following Q2 2026 results. While the company beat earnings expectations with EPS of $0.41 versus $0.3424, weak forward guidance triggered the sell-off. The stock exhibits a bearish technical signal, trading near key support levels. Fundamentally, the company maintains solid profitability metrics, including a 77.21% gross margin and a P/E ratio of 10.71, but faces headwinds from declining active client counts and AI-related market shifts.
The outlook is cautious. Analyst consensus remains a 'Buy' with a $9.25 price target, suggesting potential upside from current levels. However, near-term risks are elevated due to the guidance miss, ongoing client attrition, and potential legal investigations. The stock's valuation appears reasonable, but investor confidence hinges on the company's ability to stabilize client growth and navigate the AI disruption in the freelance market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
